Yifeng Pharmacy Chain Past Earnings Performance
Past criteria checks 2/6
Yifeng Pharmacy Chain has been growing earnings at an average annual rate of 21.8%, while the Consumer Retailing industry saw earnings growing at 3.5% annually. Revenues have been growing at an average rate of 18.4% per year. Yifeng Pharmacy Chain's return on equity is 15.1%, and it has net margins of 6.4%.
Key information
21.8%
Earnings growth rate
20.7%
EPS growth rate
Consumer Retailing Industry Growth | 12.8% |
Revenue growth rate | 18.4% |
Return on equity | 15.1% |
Net Margin | 6.4% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
We Like The Quality Of Yifeng Pharmacy Chain's (SHSE:603939) Earnings
Nov 06Yifeng Pharmacy Chain's (SHSE:603939) Solid Earnings Are Supported By Other Strong Factors
May 06Recent updates
We Like The Quality Of Yifeng Pharmacy Chain's (SHSE:603939) Earnings
Nov 06The Market Lifts Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Shares 28% But It Can Do More
Sep 27Investors Met With Slowing Returns on Capital At Yifeng Pharmacy Chain (SHSE:603939)
Jul 29Slammed 27% Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Screens Well Here But There Might Be A Catch
Jun 20Yifeng Pharmacy Chain (SHSE:603939) Seems To Use Debt Rather Sparingly
May 24Yifeng Pharmacy Chain's (SHSE:603939) Solid Earnings Are Supported By Other Strong Factors
May 06Is Now The Time To Put Yifeng Pharmacy Chain (SHSE:603939) On Your Watchlist?
Apr 13Market Participants Recognise Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Earnings
Mar 28Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Intrinsic Value Is Potentially 100% Above Its Share Price
Mar 13Revenue & Expenses Breakdown
How Yifeng Pharmacy Chain makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 23,919 | 1,523 | 6,957 | 43 |
30 Jun 24 | 23,644 | 1,505 | 6,728 | 41 |
31 Mar 24 | 23,293 | 1,482 | 6,598 | 39 |
31 Dec 23 | 22,588 | 1,412 | 6,454 | 34 |
30 Sep 23 | 22,427 | 1,437 | 6,404 | 27 |
30 Jun 23 | 21,843 | 1,391 | 6,359 | 26 |
31 Mar 23 | 21,004 | 1,330 | 6,101 | 26 |
31 Dec 22 | 19,886 | 1,262 | 5,793 | 25 |
30 Sep 22 | 17,736 | 1,016 | 5,465 | 20 |
30 Jun 22 | 16,730 | 960 | 5,175 | 19 |
31 Mar 22 | 15,845 | 919 | 4,896 | 17 |
31 Dec 21 | 15,326 | 888 | 4,721 | 16 |
30 Sep 21 | 14,646 | 867 | 4,431 | 11 |
30 Jun 21 | 14,198 | 847 | 4,185 | 10 |
31 Mar 21 | 13,726 | 798 | 3,948 | 9 |
31 Dec 20 | 13,145 | 744 | 3,711 | 8 |
30 Sep 20 | 12,324 | 698 | 3,553 | 8 |
30 Jun 20 | 11,521 | 637 | 3,375 | 7 |
31 Mar 20 | 10,855 | 583 | 3,239 | 6 |
31 Dec 19 | 10,276 | 544 | 3,124 | 5 |
30 Sep 19 | 9,636 | 526 | 2,936 | 6 |
30 Jun 19 | 8,968 | 499 | 2,716 | 5 |
31 Mar 19 | 7,900 | 463 | 2,444 | 5 |
31 Dec 18 | 6,913 | 416 | 2,163 | 3 |
30 Sep 18 | 6,054 | 402 | 1,879 | -2 |
30 Jun 18 | 5,562 | 384 | 1,722 | 0 |
31 Mar 18 | 5,211 | 345 | 1,606 | 0 |
31 Dec 17 | 4,807 | 314 | 1,496 | 0 |
30 Sep 17 | 4,480 | 285 | 1,409 | 2 |
30 Jun 17 | 4,210 | 267 | 1,326 | 0 |
31 Mar 17 | 3,978 | 241 | 1,250 | 0 |
31 Dec 16 | 3,734 | 224 | 1,170 | 0 |
30 Sep 16 | 3,540 | 210 | 1,085 | 0 |
30 Jun 16 | 3,305 | 200 | 1,002 | 0 |
31 Mar 16 | 3,040 | 187 | 933 | 0 |
31 Dec 15 | 2,846 | 176 | 873 | 0 |
30 Sep 15 | 2,615 | 169 | 806 | 0 |
30 Jun 15 | 2,492 | 161 | 766 | 0 |
31 Mar 15 | 2,373 | 150 | 721 | 0 |
31 Dec 14 | 2,230 | 141 | 678 | 0 |
31 Dec 13 | 1,804 | 99 | 547 | 0 |
Quality Earnings: 603939 has high quality earnings.
Growing Profit Margin: 603939's current net profit margins (6.4%) are lower than last year (6.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603939's earnings have grown significantly by 21.8% per year over the past 5 years.
Accelerating Growth: 603939's earnings growth over the past year (6%) is below its 5-year average (21.8% per year).
Earnings vs Industry: 603939 earnings growth over the past year (6%) did not outperform the Consumer Retailing industry 6%.
Return on Equity
High ROE: 603939's Return on Equity (15.1%) is considered low.